
Metabolic comorbidities, including central adiposity, dyslipidemia, insulin resistance, and hypertension, are common in individuals with schizophrenia and contribute to an increased risk of cardiovascular disease and related mortality. There is limited evidence quantifying the economic burden of metabolic...

Long-acting injectable antipsychotics (LAIs) have proven more effective for treating patients with schizophrenia than oral formulations. However, the use of LAIs in China remains low and this phenomenon is still under-researched. This study endeavors to provide a better understanding by systematically...

Schizophrenia poses significant challenges to the lives of individuals and to society. However, limited research has explored the relationship between stigma and quality of life in both patients with schizophrenia and their family caregivers. Furthermore, the potential mediating role of social support...